VERAXA Biotech Expands R&D Hub by Over 60%, Advancing Cancer Programs Towards Clinical Development
VRXA is trading near its 52-week low of $2.8 (4.2% above the low) on elevated volume (12× avg).
Summary
VERAXA Biotech has expanded its R&D hub in Heidelberg by over 60%, adding laboratory space and infrastructure. This expansion is to support planned team additions and accelerate its BiTAC-TCE and ADC cancer therapy programs towards clinical development. This follows the company's recent de-SPAC and Nasdaq listing on June 10th, and a June 18th 6-K announcing successful in vitro proof-of-concept for its BiTAC-ADC platform. For a small-cap biotech, this significant operational investment and explicit move towards clinical development for its core pipeline demonstrates execution and commitment post-listing.
At the time of this announcement, VRXA was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92M. The 52-week trading range was $2.80 to $27.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.